Physician profile
Michael S Cooper
NPI 1073537874
$43,524.77
in general payments reported to CMS, 2019-2025
27 companies · $361 in 2025
The $361 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $7,305 · 2021: $351 · 2022: $208 · 2023: $7,983 · 2024: $11K · 2025: $361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $15K · Food and Beverage: $2,281 · Travel and Lodging: $1,790 · Gift: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $15,000.00 |
| Food and Beverage | $2,281.36 |
| Travel and Lodging | $1,790.05 |
| Gift | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $15,094.62 | 2023-2025 | Radius Xr, Idosetr, Radius |
| Sun Pharmaceutical Industries INC. | $4,868.60 | 2019-2025 | Cequa, Xelpros, Bromsite |
| Alcon Vision LLC | $4,315.11 | 2019-2025 | Precision7 |
| Eyevance Pharmaceuticals LLC | $3,829.24 | 2019-2021 | |
| Biotissue Holdings INC. | $3,780.19 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $2,207.93 | 2023-2025 | Visumax |
| Sight Sciences, INC. | $1,532.06 | 2019-2024 | Tearcare System |
| Vertical Pharmaceuticals, LLC | $1,500.00 | 2020 | |
| Allergan, INC. | $1,160.22 | 2019 | |
| Carl Zeiss Meditec, INC. | $956.63 | 2020-2024 | Visumax, Cirrus Hd-Oct |
| Eyepoint US, INC. | $854.00 | 2019 | |
| Aerie Pharmaceuticals, INC. | $780.90 | 2019 | |
| Thea Pharma INC. | $379.24 | 2022-2023 | |
| Bausch & Lomb Americas INC. | $324.09 | 2023-2024 | Infuse, Xiidra, Miebo |
| Novartis Pharmaceuticals Corporation | $323.61 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $311.13 | 2019 | |
| Kala Pharmaceuticals, INC. | $297.00 | 2019-2021 | |
| Oyster Point Pharma, INC. | $275.76 | 2022-2024 | Tyrvaya |
| Quidel Corporation | $235.18 | 2019-2022 | |
| Dompe US, INC. | $217.21 | 2019-2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $171.70 | 2019 | |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Coopervision INC. | $31.53 | 2019 | |
| Novo Nordisk INC | $16.43 | 2020 | |
| Johnson & Johnson Surgical Vision, INC. | $12.41 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $11.18 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.